FERRARESE, Mattia
 Distribuzione geografica
Continente #
NA - Nord America 3.149
EU - Europa 2.874
AS - Asia 2.124
SA - Sud America 289
AF - Africa 61
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.500
Nazione #
US - Stati Uniti d'America 3.066
FI - Finlandia 1.922
SG - Singapore 788
CN - Cina 531
IT - Italia 261
VN - Vietnam 233
BR - Brasile 224
DE - Germania 159
HK - Hong Kong 155
GB - Regno Unito 93
PL - Polonia 75
JP - Giappone 71
ID - Indonesia 67
TR - Turchia 67
FR - Francia 66
UA - Ucraina 65
RU - Federazione Russa 47
CA - Canada 42
IN - India 41
BD - Bangladesh 39
SE - Svezia 39
MX - Messico 33
AR - Argentina 26
NO - Norvegia 22
PK - Pakistan 22
IQ - Iraq 19
ES - Italia 18
NL - Olanda 18
CZ - Repubblica Ceca 17
ZA - Sudafrica 17
BE - Belgio 15
EC - Ecuador 12
IR - Iran 12
AT - Austria 10
KE - Kenya 10
VE - Venezuela 10
MA - Marocco 9
SA - Arabia Saudita 9
IE - Irlanda 8
LT - Lituania 8
MY - Malesia 8
UZ - Uzbekistan 8
CL - Cile 7
KR - Corea 7
DK - Danimarca 6
IL - Israele 6
PT - Portogallo 6
AZ - Azerbaigian 5
CO - Colombia 5
AE - Emirati Arabi Uniti 4
DZ - Algeria 4
EG - Egitto 4
ET - Etiopia 4
GE - Georgia 4
PH - Filippine 4
TH - Thailandia 4
AL - Albania 3
CH - Svizzera 3
JO - Giordania 3
NP - Nepal 3
PY - Paraguay 3
AU - Australia 2
BH - Bahrain 2
CR - Costa Rica 2
HR - Croazia 2
JM - Giamaica 2
KZ - Kazakistan 2
LK - Sri Lanka 2
NG - Nigeria 2
RO - Romania 2
SN - Senegal 2
TN - Tunisia 2
TW - Taiwan 2
BF - Burkina Faso 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
CG - Congo 1
EU - Europa 1
GA - Gabon 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
MT - Malta 1
MU - Mauritius 1
OM - Oman 1
PS - Palestinian Territory 1
RE - Reunion 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 8.498
Città #
Helsinki 1.907
Singapore 514
Ashburn 380
San Jose 231
Chandler 212
Fairfield 195
Santa Clara 185
Beijing 173
Hong Kong 147
Woodbridge 131
Dallas 118
Ferrara 112
New York 99
Council Bluffs 91
Seattle 90
Houston 82
Ho Chi Minh City 80
Los Angeles 72
Wilmington 71
Warsaw 69
Cambridge 67
Ann Arbor 64
Tokyo 61
Jakarta 57
Munich 57
Hanoi 55
Izmir 47
Princeton 44
Jacksonville 43
Shanghai 43
Nanjing 37
Dearborn 34
Lauterbourg 33
Milan 29
São Paulo 28
Bremen 22
Orem 21
Denver 20
Chicago 17
Brooklyn 16
London 16
Oslo 16
Mexico City 15
Montreal 15
Moscow 15
Nanchang 15
Atlanta 14
Poplar 14
Boardman 13
Brno 13
Toronto 13
Falkenstein 12
Guangzhou 12
Lahore 12
Phoenix 12
Redwood City 12
Rio de Janeiro 12
San Diego 12
Da Nang 11
Rome 11
The Dalles 11
Bologna 10
Brussels 10
Dong Ket 10
Manchester 10
Shenyang 10
Hebei 9
Johannesburg 9
Tianjin 9
Baghdad 8
Frankfurt am Main 8
Haiphong 8
Jiaxing 8
Nairobi 8
Buffalo 7
Chennai 7
Kyiv 7
Mumbai 7
San Francisco 7
Stockholm 7
Tashkent 7
Turku 7
Zhengzhou 7
Amsterdam 6
Boston 6
Copenhagen 6
Fairford 6
Indore 6
Kunming 6
Nuremberg 6
Piemonte 6
Quito 6
Santiago 6
Washington 6
Andover 5
Belo Horizonte 5
Curitiba 5
Ferrara di Monte Baldo 5
Florence 5
Jinan 5
Totale 6.306
Nome #
A strategy with chaperone-like compounds to restore expression of factor IX variants affected by frequent missense mutations causing hemophilia B 2.046
Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency 304
Akt-mediated phosphorylation of MICU1 regulates mitochondrial Ca 2+ levels and tumor growth 304
Transposon-mediated Generation of Cellular and Mouse Models of Splicing Mutations to Assess the Efficacy of snRNA-based Therapeutics 244
Responsiveness of hemophilia B- causing non sense mutations to ribosome readthrough-inducing drugs strictly depends on the nucleotide and prrotein context 242
An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A 233
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation 212
Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition 210
An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics 204
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations 202
The carboxyl-terminal region of human coagulation factor X as a novel naturally-occuring linker for fusion strategies 202
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 184
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B 180
An exon-specific small nuclear u1 rna (Exspeu1) improves hepatic otc expression in a splicing-defective spf /ash mouse model of ornithine transcarbamylase deficiency 178
A Compensatory U1snRNA Partially Rescues FAH Splicing and Protein Expression in a Splicing-Defective Mouse Model of Tyrosinemia Type I 177
Protein engineering and pharmacological approaches to develop novel treatment strategies for coagulation disorders 174
The chaperone-like compound sodium phenylbutyrate improves intracellular trafficking, secretion and coagulant activity of factor IX impaired by the frequent p.R294Q mutation 169
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity 167
Mutation-specific contributions to trace factor X levels account for a life-threating phenotype in a compound heterozygous factor X deficient patient 165
A next-generation rFVIIa fusion protein with enhanced half-life as a novel by-passing tool in hemophilia 164
Exploring chaperone-like compounds as innovative therapeutic correction approach for factor IX missense mutations causing type I Haemophilia B 161
An optimized in vitro expression platform identifies Haemophilia B nonsense mutations, and thus patients, eligible for therapeutic drug-induced readthrough 159
Rational engineering of a novel factor IX albumin fusion protein results in enhanced coagulant activity and pharmacokinetic profile 158
The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies 156
Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations 155
Design of a novel factor IX albumin fusion protein with enhanced coagulant activity and pharmacokinetic profile 154
Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants 152
Design of a novel factor IX variant with enhanced procoagulant activity and half-life 152
Comparative Analysis Of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B- domain Favours Readthrough- mediated Protein Output 151
An advanced method for the small-scale production of high-quality minicircle DNA 149
Exploring chaperone-like compounds as innovative therapeutic strategy for Hemophilia B 142
Identification of novel mechanisms underlying functional response to drug-induced readthrough of haemophilia B nonsense mutations 139
Readthrough-mediated functional suppression of homozygous nonsense mutations accounts for variable bleeding phenotypes in factor VII deficiency 138
Spontaneous readthrough over recurrent F8 nonsense mutations is associated with residual factor VIII levels: implications for inhibitor risk? 124
Next generation factor VIIa with enhanced half-life 118
Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains 104
Recombinant Expression of F9 Nonsense Mutations and Fix Pharmacokinetics in Hemophilia B 98
Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association 95
null 93
Suppression of “leaky” nonsense mutations by ribosome readthrough accounts for residual factor IX levels in Haemophilia B patients 90
Totale 8.649
Categoria #
all - tutte 33.239
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.239


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202141 0 0 0 0 0 0 0 0 0 0 0 41
2021/2022358 59 35 8 4 21 22 5 12 17 31 21 123
2022/2023436 48 61 12 62 62 50 30 31 42 5 18 15
2023/2024285 10 23 16 4 17 61 15 30 6 9 12 82
2024/20251.124 36 20 97 29 130 167 20 23 178 103 181 140
2025/20264.989 299 181 229 415 460 222 374 183 2.138 329 126 33
Totale 8.649